What Is Sangamo Therapeutics, Inc.?

Sangamo Therapeutics, Inc. is a genomic medicine company that describes itself as using a multi-platform approach to gene-based therapeutics, with technologies spanning gene therapy, gene editing, cell therapy, and gene regulation. Its stated focus is translating scientific research into genomic cures for severe diseases where current medicine may offer only symptom management. The company's own materials emphasize proprietary zinc finger technology as a foundation for creating these treatments.

What Sangamo says it does

According to its website, Sangamo positions itself around a single broad mission: "Pioneering the future of genomic medicine." The company states that it uses deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients with severe diseases.

Its self-described platform scope covers four areas:

• Gene therapy
• Gene editing
• Cell therapy
• Gene regulation

This multi-platform framing is the core of how Sangamo presents itself — not as a single-product company, but as a technology developer applying several genomic tools across different disease areas.

The technology platforms

Sangamo's site lists three named technology platforms:

The zinc finger platform is the one Sangamo most explicitly ties to its identity and mission. The site does not, in the available material, break down the technical workings of each platform, so specifics beyond their names and general roles are not established here.

Therapeutic areas and programs

Sangamo lists neurology and oncology as its therapeutic applications. Its clinical programs, as named on the site, include:

• Small Fiber Neuropathy (SFN)
• Fabry Disease
• Hemophilia A

The site also references clinical trials, collaborations and partners, and patient stories tied to these conditions — including multiple patient accounts for Fabry Disease and Hemophilia A, plus one for Prion Disease and one for a renal transplant patient.

A note on the company's current status

The site's own content includes a significant disclosure: "Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction," with a link to information about a Chapter 11 reorganization and asset sales through a noticing agent. This means anyone researching Sangamo should treat the company's structure and pipeline as subject to change, and should check the noticing agent page or the company's news releases for the most current status rather than relying on older descriptions of its programs.

Where to find more

Sangamo's site organizes further detail under these sections:

• Science — technology platforms, therapeutic applications, presentations, publications
• Programs — pipeline, clinical programs, clinical trials, collaborations
• Patients — commitment, expanded access policy, bioethics, patient stories
• Investors & Media — news releases, events, presentations, ESG
• About — mission and vision, executive leadership, board of directors

For a company overview, the site points visitors to its latest corporate presentation, which it says covers vision, achievements, and roadmap.